RE: RNS29 Nov 2022 08:53
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
"CytoReason builds world-class AI disease models and we look forward with great anticipation to the outputs from their analysis of our unique repository of clinical samples and associated data from influenza human challenge trials. Indeed this is the first time that AI is being used to analyse influenza human challenge trial data which Poolbeg is proud to be part of."
"Completion of this first stage of development demonstrates yet another milestone reached in the Company's stated R&D strategy and brings us one step closer to realising the significant opportunities that arise from this partnership. There is a growing focus on AI discovered drug targets within the industry and we are assessing interest in collaboration opportunities for our AI-enabled novel targets which we expect in Q2 2023 from this programme. "
David Harel, CEO of CytoReason, said:
"Now that our influenza disease model has been enriched by Poolbeg's unparalleled data, we are excited to evaluate the novel disease mechanisms on our platform. This will potentially identify drug targets that can be used to develop treatments for influenza, a significant global health threat, in a much shorter time-frame and more cost effectively than with traditional reductionist analysis and drug discovery techniques."
.https://www.investegate.co.uk/poolbeg-pharma-plc--polb-/rns/influenza-ai-model-build-completed/202211290700088502H/